✦ LIBER ✦

Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist

✍ Scribed by Yoshitaka Yamamura; Hidenori Ogawa; Hiroshi Yamashita; Tomihiko Chihara; Hisashi Miyamoto; Shigeki Nakamura; Toshiyuki Onogawa; Tatsuya Yamashita; Tetsumi Hosokawa; Toyoki Mori; Michiaki Tominaga; Youichi Yabuuchi

Book ID: 117959647
Publisher: Nature Publishing Group
Year: 1992
Tongue: English
Weight: 1005 KB
Volume: 105
Category: Article
ISSN: 0007-1188
DOI: 10.1111/j.1476-5381.1992.tb09058.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CHARACTERIZATION OF RWJ-351647, A NOVEL

CHARACTERIZATION OF RWJ-351647, A NOVEL NONPEPTIDE VASOPRESSIN V2 RECEPTOR ANTAGONIST

✍ Joseph W Gunnet; Jay M Matthews; Bruce E Maryanoff; Lawrence De Garavilla; Patri 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB

Characterization of a novel nonpeptide v

Characterization of a novel nonpeptide vasopressin V2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes

✍ Shigeki Nakamura; Yoshitaka Yamamura; Shuji Itoh; Takahiro Hirano; Kenji Tsujima 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 169 KB

Effects of an oral vasopressin receptor

Effects of an oral vasopressin receptor antagonist (OPC-31260) in a dog with syndrome of inappropriate secretion of antidiuretic hormone

✍ LM FLEEMAN; PJ IRWIN; PA PHILLIPS; J. WEST 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB

ChemInform Abstract: An Efficient Synthe

ChemInform Abstract: An Efficient Synthesis of a Metabolite of Vasopressin V2 Receptor Antagonist, OPC-31260, by Metalloporphyrin-Catalyzed Demethylation.

✍ Yoshikazu Kawano; Kenji Otsubo; Jun Matsubara; Kazuyoshi Kitano; Tadaaki Ohtani; 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 30 KB 👁 2 views

Effects of long-term oral treatment with

Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats

✍ Masayuki Takeuchi; Jong-Dae Lee; Hiromasa Shimizu; Takanori Ueda 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 179 KB

Aquaretic Effect of Lixivaptan, an Oral,

Aquaretic Effect of Lixivaptan, an Oral, Non-Peptide, Selective V2 Receptor Vasopressin Antagonist, in New York Heart Association Functional Class II and III Chronic Heart Failure Patients

✍ William T. Abraham; Alireza A. Shamshirsaz; Kim McFann; Ron M. Oren; Robert W. S 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 175 KB